Panacea Biotec Ltd
As of 20 Nov 2026, Panacea Biotec is in Stage 4, the downtrend phase, now in week 8 (since 29 Sep 2026). It closed at ₹336, 44.7% below its 52-week high and below its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition produ… More about the company
Pro read
ProPANACEABIO is in a decline, 15% below its 200-day average. Declining stocks have lagged the market more than any other group; we wait for a base before looking again.
Its relative strength is 45 of 99, below the middle among NSE stocks over the past year. Biotechnology ranks 11 of 106 industries by the strength of its stocks, among the leaders.
Is PANACEABIO early, or has it already run? Pro answers that for every NSE stock, after every close.
PANACEABIO among Biotechnology8th of 9 by relative strength
All 9 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | ACUTAAS | Stage 2 · wk 3 | 96 | +21.6% |
| 2 | SAILIFE | Stage 2 · wk 37 | 96 | +29.2% |
| 3 | ANTHEM | Stage 3 · wk 2 | 86 | +18.1% |
| 4 | HESTERBIO | Stage 3 · wk 7 | 86 | +7.4% |
| 5 | 3BBLACKBIO | Stage 2 · wk 7 | 61 | −1.0% |
| 6 | ONESOURCE | Stage 1 · wk 1 | 58 | +18.6% |
| 7 | BIOCON | Stage 4 · wk 5 | 50 | +8.8% |
| 8 | PANACEABIO | Stage 4 · wk 8 | 45 | −1.0% |
Mutual fund holdings
Held by 1 mutual funds in portfolios to October 2026: 0 active funds and 1 index funds and ETFs.
In October, no active fund changed its holding.
All 1 funds and what each did in October
Mutual funds holding PANACEABIO: the ten largest and the month’s moves →
Panacea Biotec: quick answers
What stage is Panacea Biotec in?
As of 20 Nov 2026, Panacea Biotec (PANACEABIO) is in Stage 4, the downtrend phase. It entered Stage 4 on 29 Sep 2026 and is in week 8. What the four stages mean
Is Panacea Biotec in an uptrend?
No. Panacea Biotec is in a Stage 4 downtrend. It trades 15.4% below its 200-day average, which is falling.
How far is Panacea Biotec from its 52-week high?
Panacea Biotec closed at ₹336 on 20 Nov 2026, 44.7% below its 52-week high of ₹608. Its 52-week low is ₹296.
How has Panacea Biotec performed over the past year?
As of 20 Nov 2026, Panacea Biotec is down 17.0% over the past year and down 10.7% so far in 2026.
Which sector and industry is Panacea Biotec in?
Panacea Biotec is in the Biotechnology industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care
About this companyHealth Care· Biotechnology
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.